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Abstract
Purpose of Review Adalimumab is one of the top-selling drugs worldwide. Its imminent patent expiration has seen the emer-
gence of numerous biosimilar agents. In this article, we recap the evidence from bio-originator trials in rheumatoid arthritis (RA)
to provide context for a critical review of biosimilar trial data.
Recent Findings Currently, three adalimumab biosimilars are approved in Europe and/or the USA: Amgen’s ABP 501
(AMJEVITA/Solymbic), Boehringer Ingelheim’s BI 695501 (Cyltezo) and Samsung Bioepis’s SB5 (Imraldi). All three agents
met their pre-specified equivalence criteria. Subtle differences in adverse events and clinical responses between the reference and
biosimilar products were noted.
Summary The introduction of adalimumab biosimilars will offer exciting opportunities in improving treatment access and
increasing treatment options for RA and other licensed indications. Real-world data will further provide assurances on efficacy
as well as safety.
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Introduction
Rheumatoid arthritis (RA) is a chronic, autoimmune, systemic
inflammatory disease. If inadequately treated, it can lead to
irreversible joint damage and disability at significant costs to
the individual as well as the wider economy. Life expectancy
of patients with severe RA is reduced by 10 years on average
[1–3], whilst the total costs of RA to society were estimated at
€45 billion in Europe and $52 billion in the USA in 2006 [4].
With improved understanding of RA’s molecular patho-
physiology, increasingly targeted treatments were developed
in addition to conventional synthetic disease-modifying anti-
rheumatic drugs (csDMARDs) such as methotrexate (MTX).
Around the turn of the century, biologic drugs were introduced
that selectively targeted tumour necrosis factor (TNF). TNF
inhibitors (TNFi), along with other biologic DMARDs
(bDMARDs), formed an effective second-line for those with
inadequate response to csDMARDs and dramatically im-
proved mortality and outcomes for RA patients [5–7].
In 2002, Humira, the originator adalimumab, became the
third TNFi to be approved in the USA after infliximab and
etanercept. It is the best-selling drug worldwide, with global
sales of $18 billion in 2017 alone [8]. It is also one of the most
versatile, being additionally approved for use in ankylosing
spondylitis/axial spondyloarthritis, plaque psoriasis, psoriatic
arthritis, Crohn’s disease, ulcerative colitis, polyarticular juve-
nile idiopathic arthritis, hidradenitis suppurativa and non-
infectious uveitis [9]. It has become the benchmark agent
against which newer biologic or targeted synthetic DMARDs
are compared.
The inevitable patent expiration for TNFi stimulated
programmes to develop molecules that, whilst not identical to
the originator, could be considered to be a biological equiva-
lent of a ‘generic’. Such ‘biosimilars’ are defined as biological
agents that are similar in terms of quality, safety and efficacy to
the licensed reference product (RP) [10]. Biosimilars of
infliximab and etanercept are already established worldwide
and, for most countries, biosimilar adalimumab will enter the
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market in the last quarter of 2018 when Humira’s exclusivity
expires.
In this article, we summarise the pharmacology and clinical
efficacy of adalimumab to provide context for a critical review
of evidence from randomised controlled trials of its
biosimilars in RA. We focus on biosimilars that are approved
by the European Medicines Agency (EMA) and/or the US
Food and Drugs Administration (FDA).
Pharmacology
Adalimumab is a recombinant, fully human, IgG1monoclonal
antibody that is structurally and functionally indistinguishable
from naturally occurring human IgG1 (Fig. 1). It was
engineered through phage display technology and is produced
in a Chinese hamster ovary cell line [11].
Adalimumab is administered by subcutaneous injection,
reaching peak serum concentrations after approximately
131 h [12]. It is widely distributed, including into the
synovium. Similar to naturally occurring human IgG1, its
elimination half-life is around 10 to 14 days. Adalimumab
binds specifically to TNF-alpha (both soluble and membrane-
bound) and blocks their interaction with p55 and p75 cell sur-
face TNF receptors [12].
Despite being a fully human antibody, up to 30% of RA
patients develop anti-drug antibodies (ADAb) to adalimumab
[13]. ADAb can block the drug from binding to its target and/
or form immune complexes; they have been shown to de-
crease serum drug levels and increase markers of inflamma-
tion in RA patients [13].
Clinical Efficacy of Adalimumab
The efficacy of adalimumab in both early and long-standing
RA has been demonstrated by several phase III randomised
controlled trials (Table 1) and open-label extensions [14, 15].
For the remainder of the review, we refer to the standard dos-
ing of 40 mg every 2 weeks unless otherwise stated. Common
outcome measures included ACR responses (20, 50 or 70%
improvement in the ACR core set measurements), DAS28
remission (< 2.6), EULAR response (based on changes in
DAS28) and patient-reported physical disability assessed via
Health Assessment Questionnaires (HAQ). Radiographic pro-
gression was measured by modified or original total Sharp
score.
As monotherapy, adalimumab recipients had significantly
better outcomes than placebo in terms of function, ACR and
EULAR responses [16]. The exposure-time-adjusted incidence
Fig. 1 Adalimumab structure
compared with other TNF
inhibitors. TNFR2 TNF receptor
2, Fc fragment crystallisable
region, Fab’ antigen-binding
fragment, CDR complementarity-
determining regions, PEG
polyethylene glycol
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of adverse events (AEs) was comparable to placebo, including
serious infections and malignancies. However, as biosimilar
trials did not include monotherapy, it will not be discussed
further in this review.
Adalimumab monotherapy was not superior to MTX
monotherapy in terms of ACR response or DAS28 remission
over 2 years in the PREMIER study (of MTX naive, early RA
patients) [17]. It was, however, superior toMTXmonotherapy
at improving function and slowing/preventing radiographic
progression. Both monotherapy groups had comparable inci-
dences of AEs, including serious infections.
Adalimumab combination therapy with MTX was superior
to adalimumab or MTX monotherapies for all clinical and
radiographic outcomes in early as well as established disease
[17–19]. ACR responses were superior when standard
csDMARD treatment was combined with adalimumab than
without [20]. Incidence of AEs was similar in combination
and monotherapy groups [17–20]. Adalimumab combination
therapy with MTX was associated with higher incidence of
serious infections than MTX monotherapy [17, 19].
Other bDMARDs were similar in efficacy to adalimumab
in head-to-head trials [21–24], networkmeta-analysis [25] and
observational cohorts [26, 27]. Only IL6 inhibitors (as mono-
therapies) [28, 29] and the targeted synthetic DMARD,
Baricitinib (as combination therapy), demonstrated superiori-
ty [30].
Adalimumab Biosimilars
Biosimilar approval does not require the manufacturer to re-
establish efficacy but is instead based on the demonstration
that there are no clinically meaningful differences from the RP
[10, 31, 32]. Once biosimilarity has been established in one
indication, the drug may be approved for additional indica-
tions held by the RP without comparative clinical trials.
Extrapolation of indication reduces the number and size of
clinical trials required, thus decreasing financial cost and, po-
tentially, increasing access [32].
At the time of writing, three adalimumab biosimilars are
approved in the EU and/or the USA: Amgen’s ABP 501,
Boehringer Ingelheim’s BI 695501 and Samsung Bioepis’s
SB5. In the following sections, we will review each in terms
of clinical outcomes and trial characteristics. Other biosimilars
will be mentioned in passing, including FKB327 by Fujifilm
Kyowa Kirin Biologics which has phase III RA trial published
in abstract form [33, 34]; Sandoz’s GP2017 which has phase
III plaque psoriasis trial in abstract form [35] and has been
accepted for regulatory review [36]; and CinnoRA (Iran) and
Exemptia (India) which have published RCTs on PubMed
[37, 38]. Additional pipeline biosimilars with completed/
ongoing phase III trials are listed in Table 2. Torrent
Pharmaceuticals (India) was the second company in the world
to launch an adalimumab biosimilar, Adfrar [39]. However, its
trial evidence is not PubMed accessible and will not be includ-
ed in this review.
ABP 501
Amgen’s ABP 501 was the first adalimumab biosimilar to be
approved by the FDA in 2016 (as AMJEVITA) and by the
EMA in 2017 (as AMGEVITA/Solymbic). The manufacturer
demonstrated that ABP 501 and the RP were highly similar in
structure, function and pharmacokinetics (PK) [40–42].
Subsequent phase III studies were conducted in both plaque
psoriasis [43] and RA [44•].
The RA trial was a randomised, double-blind, active com-
parator-controlled, 26-week equivalence study, comparing
ABP 501 with US- and EU-sourced RP [44•]. Participants
did not undergo switching between ABP 501 and the RP.
The trial included 526 patients with moderate to severe active
RA despite MTX. Unlike the original RP trials, 28% of pa-
tients had prior exposure to bDMARD (but not adalimumab);
whether these participants failed prior bDMARDs due to in-
efficacy or AEs was not discussed.
The primary endpoint was the risk ratio (RR) of achieving
ACR20 at week 24, which was achieved in 74.6% of the ABP
501 group and 72.4% in the RP group (using Full Analysis Set
(FAS))—numerically higher than response rates from pivotal
RP trials. Results of the per-protocol set (PPS) analysis were
similar (raw results were not provided). The ACR20 RR was
1.039 (90%CI 0.954 to 1.133), which was within the margin
of 0.738 to 1.355 required to demonstrate equivalence.
Equivalence was also demonstrated in patients with plaque
psoriasis as monotherapy [43].
In the RA study, the RR of ACR20 for ABP 501 was 1.421
(95% CI 1.086 to 1.860) after 2 weeks, suggesting superiority
over the RP [45, 46]. This was also seen at week 12. However,
the difference was not statistically significant at other time
points. Furthermore, there were no significant differences in
secondary outcomes (ACR50/70, DAS28). The EMA there-
fore concluded that differences were likely a chance finding
rather than superiority in onset of action.
The proportions of binding ADAb (38.3 vs 38.2%) and
neutralising ADAb (9.1 vs 11.1%) were similar for ABP 501
and the RP, respectively. More patients discontinued treatment
(6.8 vs 4.6%) and the study (8.0 vs 4.2%) in the ABP 501
group; there were no specific AEs leading to withdrawal.
Liver enzyme elevations occurred in 4.9% of the ABP 501
group and in 3.8% in the RP group. This signal for ABP 501
was also seen in the psoriasis study (5.9 vs 2.5%) [43].
However, the EMA concluded that these events occurred to
a large extent in subjects with abnormal baseline values
[45, 46].
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Injection site reactions were less common in the ABP 501
group (1.7 vs 5.2%). This was also seen in the psoriasis trial
(1.3% v 3.8%) and explained as differences in the excipients
rather than biosimilarity.
BI 695501
Boehringer Ingelheim’s BI 695501 (Cyltezo) was approved
by the EMA and FDA in 2017. It was shown to be similar
to the RP in structure, function and PK [47, 48•]. Equivalence
studies were published in RA [48•], completed in plaque pso-
riasis (NCT02850965) and is ongoing in Crohn’s disease
(NCT02871635).
VOLTAIRE-RAwas a randomised, double-blind, parallel-
arm, 58-week study, comparing BI 695501 with US-sourced
RP [48•]. The trial cohort comprised 645 patients with mod-
erate to severe RA despite MTX, 27% of whom had prior
exposure to bDMARD (but not adalimumab); again, reasons
for prior bDMARD failure were not provided. At week 24,
patients on the RP were rerandomised to BI 695501 or to stay
on the RP. At week 48, all patients were entered into an open-
label extension until week 58.
Co-primary endpoints were percentage of patients achieving
ACR20 at 12 and 24 weeks (using FAS). At week 12, 67.0% of
BI 695501 recipients and 61.1% of RP recipients achieved
ACR20. The difference (5.9%; 90%CI − 0.9 to 12.7) was with-
in − 12 to 15% set by the FDA to demonstrate equivalence;
PPS results were similar (4.3%; 95%CI − 2.8 to 11.3). At week
24, 69.0 and 64.5% of BI 695501 and RP recipients achieved
ACR20, respectively. This difference of 4.5% (90%CI − 3.4 to
12.5) was within ± 15% set by the EMA (PPS 1.6%; 95%CI −
5.3 to 8.5). Secondary endpoints (ACR and EULAR responses,
DAS28, SF-36) were also similar.
There was a trend for superior ACR20 response for BI
695501 [49]. At week 4 (themost steep and therefore sensitive
part of the dose-response curve), 6.9% more of the BI 695501
group reached ACR20 than the RP group (confidence interval
not provided). Similar trends were seen at weeks 4 and 12.
However, differences between the two groups were smaller
for ACR50 and ACR70 and did not persist over time.
Another discrepancy was noted regarding persistence of
ACR20 response: 74.3% of the BI 695501 group achieved
ACR20 at week 24 but only 67.9% at week 48, while an
increase was seen in the RP group (66.8 and 70.2%, respec-
tively). Patients who switched from the RP to BI 695501 also
showed trends of falling ACR 20 response (72.3% at week 24,
64% at week 48). This was dismissed as likely a chance find-
ing since it was not seen with other outcome measures.
There were no clinically meaningful differences in propor-
tions of ADAb (BI 695501 47.4%, RP 53.0% up to week 24);
neutralising ADAb prevalence was also similar (raw results
were not provided). The number of patients with at least one
AE was 59.6% in the BI 695501 group and 60.0% in the RP
group. Several safety outcomes were in favour of BI 695501:
serious AEs (5.6 vs. 9.7%), injection site reactions (1.9 vs
5.7%), serious infections (0.6 vs 4.0%) and hypersensitivity
reactions (2.8 vs 4.6%). However, three aspects of safety ini-
tially raised the concern about the safety profile of BI 695501.
First, haematological disorders were more frequent in the con-
tinuous BI 695501 group than continuous RP group (5.2 vs
2.9%): anaemia (8 patients, 2.5%) and ‘haemoglobin de-
creased’ (2 patients, 0.6%) were reported exclusively in the
BI 695501 group. These AEs were mostly mild to moderate
and did not lead to drug discontinuation. Furthermore, five of
these patients had low haemoglobin at baseline. Second, bone
fractures occurred exclusively in the BI 695501 group (7 pa-
tients, 2.2%). This was also observed in the PK trial [47].
However, the incidence rate (20.8 per 1000 patient-years)
was within the range of bone fracture risk in the general pop-
ulation (8.5 to 36.0 per 1000 patient-years). Third, patients
who received BI 695501 more frequently screened positive
for TB (no active cases) at week 48: 8 patients (2.8%) in the
BI 695501 group, 1 patient (0.7%) in the RP group and 8
Table 2 Adalimumab biosimilar pipeline as of April 2018
Adalimumab biosimilar Manufacturer Trial status Trial registration number
FKB327 Fujifilm Kyowa Kirin Biologics Phase III completed NCT02260791
PF-06410293 Pfizer Phase III completed NCT02480153
CHS-1420 Coherus BioSciences Phase III completed NCT02489227
M923 / BAX923 Momenta Phase III (PsO) completed NCT02581345
MYL-1401A Mylan Phase III (PsO) completed NCT02714322
LBAL LG Life Sciences Phase III ongoing NCT02746380
MSB11022 Merck KGaA Phase III ongoing NCT03052322
GP2017 Sandoz Phase III ongoing EudraCT: 2015-003433-10
BCD-057 Biocad Phase III (PsO) ongoing NCT02762955
ONS-3010 Oncobiologics Phase III (PsO) ongoing EudraCT: 2015-004614-26
PsO plaque psoriasis
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patients (5.7%) in the switch group (RP to BI 695501). All
patients screened negative for TB at the start of the trial. The
EMA accepted that all three were rare events and that the
minor differences were likely a chance finding.
SB5
Samsung Bioepis’s SB5 (Imraldi) was approved by the EMA
in 2017. Again, it was similar to the RP in structure, function
and PK [50, 51•]. Its phase III study was a randomised, dou-
ble-blind, parallel-arm, 52-week trial of 544 patients with
moderate to severe RA despite MTX, comparing SB5 with
US- and EU-sourced RP. Unlike the two biosimilar trials
discussed above, all patients in this study were biologic naive
at baseline. At week 24, patients on the RPwere rerandomised
to SB5 or the RP until week 52.
The primary endpoint was ACR20 response rate at week
24 using PPS, which was achieved by 72.4% of the SB5 and
72.2% of the RP group. The difference of 0.1% (95%CI − 7.8
to 8.1) was within ± 15% required to demonstrate equivalence.
Results using FAS were similar (68.0 vs 67.4%, respectively)
with a difference of 0.8% (95%CI - 7.0 to 8.6).
ACR20 and ACR50 at week 52 showed a trend of superior
response in both SB5 and SB5/RP-switch groups compared to
the RP group, using the PPS (upper limit of CI: 15.9%, ex-
ceeding ± 15%) but not using FAS [52]. The percentage of
subjects who achieved major clinical response (ACR70 for 6
consecutive months) at week 52was 15.7% in the SB5, 15.3%
in the switch group and 9.7% in the RP group. Since the study
was not designed to show similarity at week 52, these findings
were not considered as superior response. Other response
measures (ACR50/70, DAS28) were similar.
The incidence of ADAb was similar between SB5 and RP
groups (33.1 vs 32.0% up to week 24, respectively). Overall,
treatment emergent AEs occurred in 35.8% of the SB5 and
40.7% of the RP group; 10.1 and 11.7%, respectively, were
considered related to the study drug. The number of injection
site reactions was higher in RP recipients (32 reactions in 4
patients) compared to SB5 recipients (9 reactions in 8 patients)
at week 52, although the proportions of patients were compa-
rable (3.1 vs 3.0%, respectively). The rate of discontinuation
due to AEs was lower in the SB5 than RP group (0.7 vs 3.3%
at week 24; 1.5 vs 2.4% at week 52).
Equivalence and Switching
An interesting observation in biosimilar trials was that clinical
responses in their RP groups were often different from
Fig. 2 Differences in patient characteristics between pivotal and biosimilar trials of adalimumab
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responses reported in pivotal RP trials. For example in the
EGALITYplaque psoriasis study, PASI75 response (75% im-
provement in Psoriasis Area and Severity Index) of the
etanercept RP group (76%) was much higher than in previous
RP studies (47 to 49%) [53–55]. Similarly, PASI75 response
at week 16 to the RP was 86% in the ABP 501 trial but 71 to
80% in pivotal trials [43, 56, 57]. Similar trends have also
been observed for etanercept and infliximab trials in RA
[58]. These discrepancies may be attributable to fundamental
differences in study design and/or characteristics of the study
population.
Unlike the pivotal RP trials that were mostly conducted in
North America, trials for SB5, ABP 501 and BI 695501 were
predominantly conducted in Eastern European countries
(Table 1). These patients may receive better healthcare if en-
rolled, thereby incentivising trial engagement but possibly in-
troducing bias. It is also possible that the greater response rates
were due to these patients having less severe disease. The two
Asian biosimilar trials both reported less severe disease at
baseline; their RP group also had greater response than the
pivotal RP trials (Fig. 2). These differences were less evident
for the three EMA/FDA-approved adalimumab biosimilars.
However, it is worth noting that patients in the ABP 501 and
BI 695501 trials were not all biologic naive and yet had com-
parable response rates to the biologic naive cohorts of pivotal
trials (Fig. 3); response to a second TNFi is recognised to be
poorer [59, 60]. Unfortunately, neither studies stated whether
participants stopped previous bDMARDs due to inefficacy or
AEs. There were also subtle differences in participant age,
disease duration and HAQ (Fig. 2).
These subtle differences in trial characteristics, as well as
minor discrepancies in rare safety signals, should be con-
sidered when drawing conclusions on the true biosimilarity
of these agents. This has implications for switching be-
tween the RP and biosimilars. Unlike biosimilar infliximab
and etanercept [61•], there are not many open label exten-
sion or pharmacovigilance studies for biosimilar
adalimumab. In the SB5 trial, patients receiving the RP
(n = 273) were rerandomised to switch to SB5 (n = 125)
or to continue with the RP (n = 129) at week 24, until the
end of the study at week 52. Switching had no impact on
efficacy, safety or immunogenicity [62]. An open -abel ex-
tension to 72 weeks has been published in abstract form and
reports no additional concerns [63, 64]. In the BI 695501
trial, patients receiving the RP (n = 321) were rerandomised
at week 24 to switch to BI 695501 (n = 147) or remain on
the RP (n = 148) until week 42 [48•]. A small subgroup of
patients was followed up until week 58 to assess safety.
Again, no differences were reported for efficacy, safety or
immunogenicity.
However, these RCTs were not powered to show the sig-
nificance of differences in rare AEs. In addition, trials have
stringent inclusion and exclusion criteria that may not reflect
real-world patients, such as those with comorbidities.
Therefore, pharmacovigilance studies are essential to gather
clinical evidence of the benefits and risks of switching in all
patients. We refer the reader to reference [61•] for a more
detailed discussion on biosimilar switching.
Conclusion
The year 2018 will see several biosimilars of adalimumab
emerge in clinical practices worldwide. The three EMA/
FDA-approved agents discussed in this review each have
robust RCT evidence that meet pre-defined equivalence
criteria, although subtle differences in clinical responses
and AEs between the reference and biosimilar products
were noted. As with TNFi biosimilars already on the mar-
ket, real-world data and pharmacovigilance studies are crit-
ical to developing long-term evidence to provide assur-
ances on efficacy as well as safety. These adalimumab
biosimilars, and many more in the pipeline, will offer
Fig. 3 Differences in ACR
response rates for the reference
product in pivotal and biosimilar
trials
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exciting opportunities in improving treatment access and
increasing treatment options worldwide.
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